Detection of oncogenic kinase mutations in circulating plasma DNA and correlation with clinical benefit in the phase III GRID study of regorafenib vs placebo in TKI-refractory metastatic GIST

Demetri, G.D.; Jeffers, M.; Reichardt, P.; Kang, Y.K.; Blay, J.Y.; Rutkowski, P.; Gelderblom, H.; Hohenberger, P.; Leahy, M.; Mehren, M. von; Joensuu, H.; Badalamenti, G.; Blackstein, M.; Cesne, A. le; Schoffski, P.; Maki, R.G.; Bauer, S.; Nguyen, B.B.; Xu, J.M.; Nishida, T.; Chung, J.; Lathia, C.D.; Kappeler, C.; Kuss, I.; Laurent, D.; Casali, P.G.

doi:doi:10.1158/1538-7445.AM2013-LB-295

$Detection of oncogenic kinase mutations in circulating plasma DNA and correlation with clinical benefit in the phase III GRID study of regorafenib vs placebo in TKI-refractory metastatic GIST$

Demetri, G.D.; Jeffers, M.; Reichardt, P.; Kang, Y.K.; Blay, J.Y.; Rutkowski, P.; ... ; Casali, P.G. (2013)

Detection of oncogenic kinase mutations in circulating plasma DNA and correlation with clinical benefit in the phase III GRID study of regorafenib vs placebo in TKI-refractory metastatic GIST

Article / Letter to editor

Date: 2013-04-15

Journal: Cancer Research

Volume: 73

Issue: 8

DOI: doi:10.1158/1538-7445.AM2013-LB-295

Leiden University Scholarly Publications

View statistics

In Collections

Detection of oncogenic kinase mutations in circulating plasma DNA and correlation with clinical benefit in the phase III GRID study of regorafenib vs placebo in TKI-refractory metastatic GIST